• Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs
• Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia
• The company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptoms
• Tryp has announced two new collaborations for oversight of the drug trials this month; consultants with Fluence and Clinlogix will help to ensure the quality of the tests

Bioscience pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), pursuing its goal of developing psychedelic drug treatments for diseases that otherwise have unmet medical needs, is continuing to prepare for an upcoming Phase 2a clinical trial for treating eating disorders by forging partnerships with professionals experienced in conducting such trials.

The company’s recent announcement that it will collaborate with psychedelic therapy educational platform Fluence in a master service agreement to provide design and training for the psychotherapeutic portion of the upcoming trials follows on the heels of Tryp’s agreement with the University of Florida to conduct the clinical trial.

Pediatric medical researcher Jennifer Miller, M.D., of the University of Florida is leading the investigation into the potential of Tryp’s TRP-8802 psilocybin product for safety, pharmacokinetics and efficacy. Miller is an expert in certain eating disorders including binge eating and hyperphagia.

“There are currently no approved drugs and only limited options to treat patients with rare over-eating disorders,” Miller stated in a news release announcing the collaboration (https://ibn.fm/rSnYK).

The company’s upcoming Phase 2a trial for fibromyalgia patients is designed to provide an alternative treatment option for the large number of patients currently relying on opioids to relieve their symptoms.

Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients, according to another news release issued May 3 (https://ibn.fm/SO55k).

“In the fast-moving arena of psychedelic therapies, Fluence has established themselves as the leader in psychotherapy design and training,” Tryp President and Chief Science Officer Jim Gilligan stated in the news release. “Psychotherapy is an essential component of the effective administration of our innovative psilocybin formulations for the chronic pain and eating disorder indications that we are pursuing. Fluence’s experience with training hundreds of clinicians combined with the training protocol they are creating with Tryp will help create a safer and more effective treatment protocol for our clinical trials and ultimately for patients suffering from these conditions.”

Additionally, Tryp announced May 10 that Contract Research Organization (“CRO”) Clinlogix will provide support services for the upcoming Phase 2a trials (https://ibn.fm/V0Zr7). Clinlogix has developed experience in providing CRO services for the development of novel pharmaceutical products on a global basis, and the master service agreement between Tryp and Clinlogix will support the development of Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFNTM”) program, according to the announcement.

“The proper execution of a clinical study is of paramount importance in order to achieve clinical success; working with the team from Clinlogix provides Tryp with key elements needed for the conduct of a successful clinical study,” Gilligan added.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

 

• SRAX Inc. will host conference call to announce Q1 2021 results on May 17, 2021
• Call will be hosted via live video call, will also feature question & answer session
• SRAX released Q4 2020 results earlier this year, revealing 316% YoY increase in revenues, upping its 2021 sales guidance to $23-25 million

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, is scheduled to host a conference call to discuss its Q1 2021 results on May 17th, 2021. The call will feature SRAX Founder and CEO Christopher Miglino as well as SRAX CFO Michael Malone, who will provide investors with an operational and financial summary of their quarterly earnings on a live video call, along with hosting a question-and-answer session, on May 17, 2021 at 1:30 pm PT/4:30 pm ET (https://ibn.fm/wHuuS).

SRAX has seen its financial returns go from strength to strength over the past year. Earlier this year the Company released its Q4 2020 results (https://ibn.fm/rP4Mm). At the time the Company reported Q4 revenues of $4.5 million, up 316% year-over-year whilst simultaneously reporting Q4 net income of $200,000, a significant increase relative to the net loss of -$4.4 million witnessed in Q4 of 2019.

SRAX also seized upon the opportunity to raise its FY2021 revenue guidance to $23-25 million, a substantial increase from its previous guidance of $17-18 million, implying a growth rate of between 164-187% year-over-year for FY2021.

SRAX also provided an update on Sequire at the time, revealing that the investor intelligence platform had secured bookings of $4.8 million and $10 million for the fourth quarter of 2020 and first quarter of 2021, respectively, whilst also seeing its corporate subscriber base swell to 183 publicly listed companies (versus 92 companies as of their Q3 2020 update). SRAX also announced that Sequire would recognize $16.5 million in revenues based on its existing contracts over the course of the 2021 fiscal year.

“We are making great progress with our platform and we are seeing continued adoption of the products that we are building for issuers,” stated SRAX CEO Christopher Miglino following the Company’s Q4 2020 results. “We had another record quarter of bookings for Sequire. In the first quarter of 2021 we have closed over $10 million in contracts.”

SRAX has taken several steps to augment and streamline its operations over the past few months, including naming entrepreneur and 2020 presidential candidate Brock Pierce to the Company’s board of directors, divesting an equity stake in TI Health (formerly known as SRAXmd), and announcing a substantial line-up of investor conferences to be held via the Sequire platform over the coming year.

With Sequire’s popularity rising to new heights among both corporate issuers and investors alike, SRAX stands well poised to benefit from its success.

To register for the live webcast and view the presentation, please sign up at the following link: https://Q12021earningscall.mysequire.com.

Investors who would like to access the earnings call by phone can use the following details:

Phone Number: +1 669-900-6833 | Webinar ID: 959-8207-6042 | Passcode: 288501

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Clean Power Capital Corp.’s investee company PowerTap Hydrogen Fueling to employ its patented hydrogen production technology in several commercial markets
• PowerTap utilizes data analytics to control PowerTap’s system performance
• PowerTap aims at installing 500 hydrogen filling stations in the USA alone within the next 3-5 years

Clean Power Capital (NEO: MOVE) (FWB: 2K6A) (OTC: MOTNF) is an investment holding company that focuses on investor and finance opportunities across renewable energy, bio-medical, pharmaceutical, and naturopathic sectors. The company’s investments are geared towards short-term gains, income generation, or long-term capital appreciation, with the main objective to generate maximum returns from its investments.

PowerTap Hydrogen Fueling Corp., an Investee Company Of Clean Power Capital, holds a unique and patented hydrogen production technology (PowerTap). PowerTap is focused on building affordable hydrogen fueling infrastructure through its eco-sustainable and expandable product design for the modularized and onsite hydrogen production facility and launch plan.

A previous generation of PowerTap technology is already operational (not owned by PowerTap Hydrogen Fueling Corp.) across several hydrogen fueling stations in the public and private enterprises of California, Massachusetts, Maryland, and Texas. With this business model, Powertap Hydrogen Fueling aims to operate up to 500 hydrogen filling stations in the USA alone within the next 3-5 years. As per the company’s latest announcement, the PowerTap’s 3rd generation units will be utilized towards several commercial markets.

As a part of its progressive expansion plans, PowerTap has started initial discussions with various cities, states/provinces about partnerships with new verticals such as commercial buses and trains. The company’s 3rd generation onsite hydrogen production module will be made available to hydrogen fuel cell cars and trucks and provide blue hydrogen for trains and buses.

The expanding hydrogen public bus fleet is another vertical that could leverage PowerTap’s blue hydrogen production and dispensing technology. Pioneers in operating a hydrogen fuel-cell electric bus2, the Orange County, California Transit Authority (“OCTA”) is a public transportation agency in Southern California.  During the model program, OCTA operated the first hydrogen bus in a similar way to the other OCTA buses in the fleet.  According to the California Fuel Cell Partnership, fuel cell buses are environmentally-sustainable with lesser noise, no local emissions, and a substantial reduction in greenhouse gas emissions (https://ibn.fm/T7KIE).

As a further step-up to the potential of PowerTap’s 3rd generation units, these modules will use advanced operating software with data analytics to control every aspect of PowerTap’s system performance. Kelley Owen, PowerTap’s Chief Operating Officer stated that the advancements of the PowerTap 3rd generation hydrogen production fueling stations will maximize the company’s first-mover advantage.

PowerTap employs advanced operating software to collect and feed data to the cloud where a data analytics application will deploy advanced algorithms to monitor performance characteristics.  This will result in the substantial reduction of extending the longevity of the 3rd generation units while reducing the overall cost of onsite hydrogen production (https://ibn.fm/TFlTU).

For more information, visit the company’s website at www.CleanPower.Capital.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• World Nuclear Association notes that new nuclear builds offer advantages that extend beyond simply being clean, reliable source of energy
• With growing demand for carbon-free energy production, growing reliance on nuclear seems certain
• Uranium, the fuel most widely used to power nuclear plants, will become an increasingly vital mineral

While COVID-19 still looms as a potential threat in parts of the world, some positive signs indicate that the worst might be over. In its “World Nuclear Performance Report 2020,” the World Nuclear Association noted that, in a post-pandemic world, new nuclear builds offer advantages that extend beyond simply being a clean, reliable source of energy. Uranium Energy (NYSE American: UEC) stands ready to support and contribute to growth in the nuclear energy space.

“In 2020 the nuclear industry has been an essential part of the response to the coronavirus pandemic,” writes World Nuclear Association director general Agneta Rising in the preface to the report. “Despite the challenges of working in COVID-safe conditions, nuclear operators have ensured reactors have been available to provide electricity and grid stability. Reactor operators have also had to respond to the marked reductions in demand that have been observed during the pandemic and have had to operate with more flexibility. . . .

“Looking forward, governments are considering at how to restart their economies and generate jobs, as well as how to meet their energy and environmental goals,” Rising continues. “Each new nuclear build project generates thousands of jobs and boosts the local economy, as well as contributes to our harmony goal of a clean and reliable electricity mix.”

The performance report (https://ibn.fm/NVpMo) noted that electricity generated from the world’s nuclear reactors increased for the seventh consecutive year in 2019, reaching the second highest output ever. With a growing demand for carbon-free energy production and the safe, clean and highly reliable energy that nuclear power provides (https://ibn.fm/1j1ik), new nuclear builds seem certain.

With those new builds will come a greater need for uranium, the fuel used to power nuclear plants. Uranium Energy Corp, a U.S.-based uranium mining and exploration company, is poised to benefit from the increased demand projected for uranium. The company has fully licensed projects in Texas and Wyoming with a production profile of 4 million pounds per year, enough to power about eight of America’s 93 commercial reactors. UEC has a solid balance sheet with over $110 million in cash, equity and inventory holdings. They control one of the largest databases of historic uranium exploration and development in the United States, an invaluable resource as the company has been able to identify potential acquisition properties that have already been the subject of significant exploration and development in the past.

UEC is positioned as the leader in U.S. low-cost, environmentally friendly and fully permitted In-Situ Recovery (“ISR”) projects (https://ibn.fm/erkyy). Their Burke Hollow project’s initial production area is amongst the largest uranium ISR wellfields ever developed in the 45-year history of uranium mining in South Texas. The low-impact ISR method of uranium recovery being developed at Burke Hollow is the most environmentally friendly way to mine uranium which is now responsible for approximately 50% of global production (https://ibn.fm/6FkaI).

Founded in 2003, UEC is headquartered in Corpus Christi, Texas. Properties acquired by the company are primarily located within the United States, including Texas, New Mexico, Colorado, Arizona and Wyoming. In addition, the company is aggressively pursuing other key developmental targets. UEC is investing to be a next-generation uranium producer, and is committed to providing low-cost, low-capital fuel for the country’s large electricity-generating nuclear fleet.

For more information, visit the company’s website at www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC

• Imagin Medical’s contract manufacturer, Lighthouse Imaging, has developed a program focused on refining the i/Blue System’s design for manufacturing
• Lighthouse’s manufacturing process will ensure that regulatory standards are followed while maintaining optimal performance and staying within targeted costs
• Imagin is currently focusing on using the i/Blue system for bladder cancer visualization with plans to extend the use of the technology to other procedures in the future

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is on track to complete its patented i/Blue Imaging System(TM) in 2022. The innovative technology leverages proprietary light sensors and optics to improve the accuracy and efficiency of bladder cancer visualization and removal, potentially reducing recurrence rates.

The manufacturing progress reported to-date can be largely attributed to the company selecting Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified manufacturer, as its contract manufacturer. According to a press release, Lighthouse’s development program is focused on refining the i/Blue system’s design to ensure that the final device complies with all regulatory standards while maintaining optimal performance and remaining within a target cost and anticipated demand (https://ibn.fm/B6kXW).

Imagin Medical Director of Engineering and Quality Mike Vergano explained that the company chose Lighthouse to help move the i/Blue System into commercial manufacturing because of its cross-functional expertise in electronics, optics, software and mechanical design. He added that Imagin was very satisfied with Lighthouse’s manufacturing progress: “We have not been disappointed. The Lighthouse team’s work to-date has been exceptional, and we look forward to that continuing.”

Imagin President and CEO Jim Hutchens also said his company expected Lighthouse to remain on schedule and meet all manufacturing targets. This year’s primary goal is the completion of the final pre-production i/Blue Imaging System unit, as outlined by Hutchens in a press release earlier this year. The company’s secondary goals include establishing final test parameters for the technology with the FDA, continuing to develop relationships with opinion leaders in the field and expanding its intellectual property platform (https://ibn.fm/ZwUKV).

While the company has plans to expand its technology to other minimally invasive procedures, the primary focus for now is on bladder cancer, one of the most expensive forms of cancers to treat. Bladder cancer is the sixth most prevalent cancer in the U.S., with one of the highest recurrence rates, greater than 50%. In 2020, there were 81,400 new cases reported and approximately 17,980 deaths (https://ibn.fm/lwm6S).

The current standard of treatment for bladder cancer is the cystoscopy, a procedure that allows doctors to examine the lining of the bladder by inserting a hollow tube (cystoscope) equipped with a lens into the bladder. Approximately 90% of all cystoscopies use white light which, however, cannot detect all of the cancerous growths if they run flush along the bladder’s lining. Introduced a decade ago, the use of an FDA-approved contrast agent with a blue light filter allows surgeons to better visualize flat surface cancerous growths, enabling a cleaner resection, but has the downside of not showing images in real time, requiring surgeons to switch back between white and blue light images to orient themselves within the bladder.

Imagin Medical’s innovative i/Blue Imaging System, based on advanced optics and light sensors that employ patented ultrasensitive imaging technology, aims to address these limitations by simultaneously displaying white light and blue light images in real time, side-by-side on the screen, providing better visualization for the surgeon and potentially lowering recurrence rates. Additionally, the i/Blue Imaging System adapts to most endoscopes already on the market, thus providing a more cost-effective solution for hospitals.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Healthy Extracts Inc. announces the addition of Dr. Joel Kahn, M.D., a world-renowned, triple board-certified cardiology specialist to its medical board
• Dr. Kahn has personally conducted clinical studies that confirm the benefits of Citrus Bergamot SuperFruit(TM) for cardiovascular health
• Citrus Bergamot SuperFruit(TM), the main ingredient in BergametNA’s product line, is the super fruit alternative to prescribed cholesterol medications

Healthy Extracts (OTCQB: HYEX), through its developing and acquiring complementary companies, is engaged in manufacturing plant-based formulations dedicated to heart and Brain health. With its focus towards strengthening its position in the multibillion-dollar nutraceuticals market, the company has already launched its science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries.

Healthy Extracts Inc. recently announced the addition of Dr. Joel Kahn, M.D., a world-renowned, triple board-certified cardiology specialist, to the company’s medical board. Dr. Kahn has used the BergametNA Citrus Bergamot SuperFruit on thousands of patients and approved the product’s cardiovascular health benefits of positive arterial age reversal and arterial flexibility (https://ibn.fm/M30IC).

Duke Pitts, director, president, and CEO of Healthy Extracts Inc. said that they were excited to welcome Dr. Kahn, one of the few triple-certified cardiologists in the U.S, to their company’s medical board. He further said Dr. Kahn’s decision to join the company’s medical board, based on the Kahn Center for Cardiac Longevity CIMT test results, was an exciting development. Duke Pitts also said that his addition to the company’s already talented team of specialized doctors will be instrumental in expanding their doctor-to-doctor and consumer sales.

For more information on heart health, watch Dr. Kahn’s press release video.

Dr. Kahn, whose cardiology career spans 30 years, has been studying natural health, integrative cardiology, and wellness cardiology over the last decade. He expressed his pleasure in joining the Healthy Extracts Inc. medical board. He also said that physicians across North America should be educated about the benefits of BergametNA’s product formulations and how it can assist doctors in treating patients naturally. Dr. Kahn has personally conducted clinical studies that confirm the virtues of the super fruit Citrus Bergamot SuperFruit, the main ingredient in BergametNA’s product line.

For more information, visit the company’s website at www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts Inc. (OCTQB: HYEX) serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.

Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents – two issued and four pending.

For more information visit: www.healthyextractsinc.com, www.bergametna.com or www.fuel4thought.com

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2020, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Healthy Extracts Inc.
Las Vegas, Nevada
www.healthyextractsinc.com
info@healthyextractsinc.com
720-463-1004

Corporate Communications:
InvestorBrandNetwork (“IBN”)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• Alcoholic beverage companies have recently benefitted from surge in investor interest, as shown by recent record share price achieved by Italian beverage group, Campari
• Investors are increasingly betting that consumers will seek to channel increased savings into discretionary expenditure, including dining out, alcoholic beverages
• Splash Beverage has sought to broaden its multi-brand portfolio through recent purchase of Copa di Vino, leading wine-by-the-glass producer
• Company has leveraged synergies within the group, recently signing distribution deal with Copa di Vino’s distributor for in-house tequila brand, SALT

On Wednesday, May 5, 2021, Campari’s share price touched a new record high. The Italian alcoholic beverage group may be relatively small by global standards – the company’s 2020 revenues amounted to $2.02 billion, a mere fraction relative to global drinks giant Diageo’s $14.8 billion, or beer brewer Anheuser-Busch’s $46.9 billion. However, its recent share price rally is a clear illustration of the optimism currently pervading the beverage sector—an optimism which has also spread to buoy sector peers such as Splash Beverage Group (OTCQB: SBEV), a holding company for a leading portfolio of beverage brands. Global investors are increasingly betting that consumers who set aside savings while confined to their homes during months of COVID-19 curbs will raise their expenditure on everything from clothes and travel to dining out and drinks once allowed to do so. Some have drawn comparisons to the years of festivities which followed the culmination of World War I (https://ibn.fm/Z5OCD). “You really have revenge conviviality,” said Campari CEO Bob Kunze-Concewitz during a recent interview. “Frustrated by a long period of lockdown, people have a strong, strong urge and need to meet their family and friends. That’s feeding into increased sales of spirits.” A resurgence in demand for alcoholic beverages, coupled with the recent expansion of their product portfolio, has also worked out to the benefit of Splash Beverage Group, which has been able to exploit the natural synergies present within its portfolio. The company, which recently announced the acquisition of the Copa di Vino Corporation, a leading producer of premium wine by the glass, revealed that it had entered into a distribution agreement with Copa de Vino distributor, Pepin Distributing, for its SALT Naturally Flavored 100% Agave Tequila line (https://ibn.fm/v73hJ). “We’re honored to be in business with the Pepin family enterprise in SE USA,” stated Splash Beverage President and CMO Bill Meissner. “It further proves the synergy among our portfolio of brands and our ever-expanding relationships with each of our distributors. The acquisition of Copa di Vino was a boon for us in a number of ways, and this further proves out our investment model, which is conducive to exponential growth as we continue to expand our sales force and selective acquisitions and/or brand developments.” Liquor sales in the United States rose by 7.7% in 2020, with tequila the clear sector leader – sales of the beverage rose by over 46% over the last year (https://ibn.fm/m6NvP), outpacing most other alcohol categories – in turn, resulting in rising sales for Splash’s SALT tequila brand. Meanwhile, newly acquired Copa di Vino has been a significant beneficiary of the increased tendency for consumers to consume wine outside of traditional hospitality venues as well as in smaller, single-serve volumes. The company, a leading producer of premium wine by the glass in the United States, has looked to specialize in providing consumers with a ready to drink wine glass designed to go anywhere without the need for a bottle, corkscrew, or glass. With the liquor industry and the wider market both betting on a resurgence in alcoholic beverage demand, Splash Beverage Group’s multi-brand portfolio provides investors with an enticing proxy through which to benefit from the global economy’s ongoing reopening. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• Founded by two career biotech veterans who had perfected grape cultivation and were ready to further diversify their organic farm
• The climate in Sonoma County is ideal for grapes and also for cannabis
• Produces premium quality cannabis at a fraction of the cost of its competitors

Sonoma Biologics, an ultra-premium cannabis grower located in California wine country, was founded by Paul Caracciolo and his wife, Margaret, both out of the biotech industry.  They founded Mill Station Vineyards in Sonoma, planning to perfect their winemaking craft, and establish an organic farm, according to an article in USA Today (https://ibn.fm/3Ysr7). With 8.5 acres of ultra-premium Pinot Noir grapes, they began to gain a reputation and world-class winemakers started buying their grapes. Their grapes can be found in some of the most coveted Pinot Noirs in the Russian River Valley of Sonoma county. Having worked in the biotech industry and seeing the world through the lens of science, they viewed Sonoma as a laboratory. This influenced everything they did and helped them develop standard protocols for cultivation that were precisely calibrated to create the high-quality grapes they now grow. The climate in Sonoma County is ideal for grapes and also, as it turned out, for cannabis as well. In 2016 California approved the 2016 voter initiative to legalize cannabis. Paul and Margaret knew they were well-positioned to diversify and enter one of the fastest-growing industries in the region. When they decided to move into cultivating cannabis, the two applied the same basic principles they used in the growing of grapes. Just as other winemakers came to them for their grapes, Cannabis start-ups reached out to them for varietal knowledge in Sonoma county, as the Caracciolos had already tested and piloted tens of varietals in their first year for climate suitability. “There are a lot of analogies when it comes to irrigating and scaling these two farming products,” said Caracciolo. “Having grown grapes on the scale we had been, really gave us a head start in the cannabis business. All other factors being equal, it can’t be overstated that being enthusiastic and passionate about your products isn’t enough. It really helps to know and understand the science to take your product to the next level.” Sonoma Biologics adheres to the strictest standards required by both the California Department of Agriculture and the Sonoma county agricultural standards and regulations. The Company has successfully passed California’s laboratory purity testing for the past three years. By using exclusively organic methods to grow and taking advantage of the suitable Sonoma county climate, the Company produces premium quality crops at a fraction of the cost of its competitors. Sonoma Biologics has acquired land in Sonoma County and Mendocino County, with additional expansion targeted for Lake County. The goal is to become one of the largest organic-equivalent, environmentally friendly suppliers in northern California through acquisitions, joint ventures, and revenue-sharing cultivation opportunities. With years of experience in large-scale commercial farming, including 100 acres of hemp grown in 2019, the team at Sonoma Biologics is well-positioned to expand rapidly towards a vertically integrated operation. For more information, visit the company’s website at www.OwnSonomaBiologics.com. NOTE TO INVESTORS: The latest news and updates relating to Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma

• BRSF made strides on operations front to improve lead times, quality control
• Company experienced revenue growth, increase in assets and R&D
• Brain Scientific has identified that only 30% of U.S. hospitals have equipment for routine EEGs due to cost and space constraints

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, announced it has filed its annual report for the fiscal year that ended Dec. 31, 2020 (https://ibn.fm/GCazt). The company reported key business highlights and substantial growth as well as outlined milestones expected to be completed over the next two years. “In 2020, Brain Scientific made good progress toward our vision of introducing transformative brain diagnostic solutions that apply cutting-edge technologies and establish a new innovative norm for clinicians,” said Boris Goldstein, chairman of the board of directors. “We made strides on the operations front to improve lead times and quality control, as well as connections to expand our customer base in early 2021.” From 2019 to 2020, BRSF experienced a revenue growth from $489,202 to $544,275, and an increase in assets from $291,002 to $440,218. The company’s liabilities also increased, with 80% of the increase coming from the addition of derivative liabilities and convertible notes payable. The research and development efforts of the company also increased, up an impressive 266% from the previous year. The company’s two FDA-cleared products, the NeuroCap(TM) and NeuroEEG(TM), will soon be manufactured in the United States, with a rollout to follow in the Canadian market. Currently, both devices are available on a limited basis to ICUs, acute care settings and other emergency departments throughout the country. Brain Scientific has developed innovative products that are disrupting the EEG norms. The NeuroCap, a disposable pre-gelled headset, is disposable and easy to set up. It offers a cost-effective EEG solution to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired. The NeuroEEG is a portable, wireless and cost-effective EEG system that fits in the palm of a hand, and requires minimal training to use. Throughout 2020 and the global pandemic, the need for disposable, easy, and quick-to-use EEG options became even more evident. The NeuroCap and NeuroEEG help minimize contact between patients and the medical worker, provide a more sanitary solution, and can be used in a broad variety of settings. In fact, BRSF has identified that only 30% of U.S. hospitals have equipment for routine EEGs due to cost and space constraints. The devices’ accessibility and quality have made it ideal for use in R&D as well, from concussion research (https://ibn.fm/ybdot) to potentially uncovering new treatment options to reduce autism symptoms in children (https://ibn.fm/1zraT). For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Simple design enables consumers to prevent medication errors
• Offers 12 different functionalities with the newest addition of GoodRX
• Now offering up to 85% discount on most medications at over 70,000 pharmacies Across the United States. Powered by GoodRX
• Download the APP now and not only manage your medication but save money every time you walk into your local Pharmacy by having your coupons ready

United Medical Equipment Business Solutions Network (“UME”) is in the business of helping families with medical resources, supplies and providing a network of reliable solutions. One of these solutions is the Medication Management App, developed to provide direct and indirect patient care and education for care professionals, caregivers, students, and family members. The simple design enables consumers to prevent medication errors by providing quick information in the convenience of one available app on the iOS and Android platforms.

The free initial download allows for basic app functionalities. These include access to:

• Medication Dictionary
• Pill Identifier
• Weight Converter
• Temperature Converter
• Volume Converter
• Height Converter
• Dosage Converter

A monthly subscription fee or discounted yearly fee unlocks the professional functions that include:

• Y-Site IV Compatibility
• HIPAA Secure Messenger
• Medication Log-Reminder
• Good RX
• UME Elite Education

GoodRX is the newest addition to the app’s functions. This feature allows users to view discount prices and coupons while managing medications all within the app. Without leaving the Medication Management App, the user can compare prices between pharmacies, access free coupons for their prescriptions, and show the coupon to the pharmacist when picking up the prescription. All of this without having to leave the one convenient app location.

Coupons and discounts for prescriptions are not all that GoodRx brings to the Medication Management App. In addition, GoodRX offers same-day appointments with an online healthcare provider, access to at-home lab tests or tests at a nearby service center, and all at minimal costs. The company also brings additional information to the platform that has been reviewed for accuracy by medical and healthcare experts. Articles span from healthy living and disease management to healthcare costs and ways to save.

The Medical Management App is one more way that United Medical Equipment is providing reliable resources and solutions to fit the ever-changing needs of an aging population.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed